术前精神药物治疗并非髋或膝关节置换术后12个月患者报告改善较差的风险因素:一项基于多中心登记的7,247例手术队列研究
该多中心登记队列研究纳入丹麦三个快通道科室2016至2020年因原发性骨关节炎行初次髋关节置换4,021例和膝关节置换3,226例,发现术前精神药物治疗与术后12个月牛津髋/膝评分改善无显著关联,但与基线及随访时评分略差相关,作者认为从患者中心角度看关节置换术仍为有效治疗。
要点
- 术前精神药物治疗与髋/膝关节置换术后12个月患者报告改善无显著关联。
- 术前精神药物治疗者基线及12个月随访牛津评分略差,但改善幅度与未用药者相当。
- 作者认为,从患者中心角度看,尽管存在术前精神药物治疗,关节置换术仍为有效治疗。
核心结论
- 在髋和膝关节置换术中,术前精神药物治疗不是术后12个月患者报告改善较差的风险因素。
- 术前精神药物治疗与略差的基线和随访评分相关,但从患者中心角度看关节置换术仍为有效治疗。
研究设计与样本
- 多中心登记队列研究,纳入丹麦三个快通道科室2016至2020年因原发性骨关节炎行初次髋关节置换4,021例和膝关节置换3,226例,共7,247例手术。
- 暴露状态依据丹麦国家处方登记确定,采用多水平Tobit回归估计边际均值差(MD)及95%CI,并校正年龄、性别和查尔森合并症指数。
主要发现
- 术后12个月,术前精神药物治疗与牛津髋评分改善无显著关联(MD -0.5,95%CI -1.4至0.4)。
- 术后12个月,术前精神药物治疗与牛津膝评分改善无显著关联(MD -0.3,95%CI -1.2至0.5)。
- 术前精神药物治疗与较低的基线牛津髋评分(MD -1.4,95%CI -2.2至-0.6)和牛津膝评分(MD -2.1,95%CI -2.9至-1.3)相关。
- 术前精神药物治疗与较低的12个月随访牛津髋评分(MD -1.9,95%CI -2.8至-1.1)和牛津膝评分(MD -2.4,95%CI -3.2至-1.6)相关。
- 在其他时间点、使用EuroQol-5 Dimensions-3 Levels/EuroQol-5 Dimensions-5 Levels或EuroQol视觉模拟量表以及评估术前精神药物治疗亚组时,观察到相似结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative psychopharmacological treatment (PPT) has been associated with increased hospital length of stay and readmission rate after hip and knee arthroplasty. However, little is known regarding the association between PPT and improvements in patient-reported outcomes postoperatively in a multicenter fast-track setting. Thus, the primary objective was to investigate whether PPT is a risk factor for poorer patient-reported improvements 12 months after surgery. Secondary objectives included assessment of additional time points and subgroups of PPT. METHODS: This multicenter registry-based cohort study included 4,021 primary hip and 3,226 primary knee arthroplasties performed from 2016 to 2020 at three fast-track departments in Denmark due to primary osteoarthritis. The Oxford Hip Score/Oxford Knee Score (OHS/OKS), EuroQol-5 Dimensions-3 Levels/EuroQol-5 Dimensions-5 Levels, and EuroQol visual analog scale were collected at baseline and 3, 6, 12, and 24 months after surgery. Exposure status was assigned using the Danish National Prescription Registry. Marginal mean differences (MD) with 95% confidence intervals (CIs) were estimated using multilevel Tobit regression and adjusted for age, sex, and the Charlson Comorbidity Index obtained from the Danish National Patient Register. RESULTS: No associations were found between PPT and improvements in OHS (MD -0.5, CI -1.4 to 0.4) or OKS (MD -0.3, CI -1.2 to 0.5) after 12 months. However, PPT was associated with lower baseline OHS (MD -1.4, CI -2.2 to -0.6) and OKS (MD -2.1, CI -2.9 to -1.3), and 12 months follow-up OHS (MD -1.9, CI -2.8 to -1.1) and OKS (MD -2.4, CI -3.2 to -1.6). Similar findings were observed at other time points, using EuroQol-5 Dimensions-3 Levels/EuroQol-5 Dimensions-5 Levels or EuroQol visual analog scale, and when evaluating PPT subgroups. CONCLUSIONS: In hip and knee arthroplasty, PPT was not a risk factor for poorer patient-reported improvements 12 months after surgery. However, PPT was associated with marginally poorer baseline and follow-up scores. Thus, arthroplasties remain effective treatments despite PPT from a patient-centered perspective.
引用
- Kornvig S, Kehlet H, Jørgensen CC, et al. Preoperative Psychopharmacological Treatment Is Not a Risk Factor for Poorer Patient-Reported Improvements 12 months After Hip or Knee Arthroplasty: A Multicenter Registry-Based Cohort Study of 7,247 Procedures. J Arthroplasty. 2024. PMID: 39419411. doi:10.1016/j.arth.2024.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。